Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > PMN wishes from three weeks ago..
View:
Post by Mole101 on Apr 15, 2021 9:16am

PMN wishes from three weeks ago..

ProMIS plans to accelerate progress toward a number of top priorities, including:

  • Advancing the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
  • Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data;
  • Expanding our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform;
  • Advancing our partnered diagnostic programs;
  • Achieving NASDAQ listing;
  • Expanding our Board of Directors; and
  • Expanding our management team, capitalizing on the talent pool in Boston, to support a growing and ambitious scope of activity.
  •  
Comment by BottomBroker on Apr 15, 2021 9:33am
Yep.  Now let's hope some of that actually comes true. 
Comment by Speyeder999 on Apr 15, 2021 11:20am
The fundamentals haven't changed over the last three weeks, so where did the demand go for the stock? Last week, millions of shares bought at 22 cents. This week, price tanks +20% and barely any buyers? Or, no sellers? One day, I'll figure out how all this works, lol  
Comment by DavidKingCanada on Apr 15, 2021 11:56am
PMN.to is a long term buy and hold. The new Investors and their debentures expire in 2026. Their goal is to to be listed on the Nasdaq meaning the Stock Price will only rise. Once you notice people are buying and the price is not going up, you can always sell and buy in at a lower point and own more shares. PMN.to is not going anywhere and will contine to strive!
Comment by G1945V on Apr 16, 2021 6:38am
The long and short of it....... Clinical Trial....... Clinical Trial......Clinical Trial.  The new investors need to put up more cash and get things going if their goal is to list PMN on Nasdaq.  G1945V
Comment by Mole101 on Apr 16, 2021 8:49am
I think # 2 is the key to move forward and upward. The talk has been for many years that active discussions were underway, it's time to show the fruits and either sale or create a joint venture in one or several of the other products that PMN has in the books . That would prevent dilution and bring new money into the company . It's pointless to own a bunch of great products if they just ...more  
Comment by M101 on Apr 16, 2021 12:01pm
Exactly, and that's why all the other aspirational statements are just excuses to delay. 
Comment by retiredcop on Apr 16, 2021 12:42pm
The little.problem could come up with more investment by the new group....if they add any more.money in the same.method they did previously .. ..they run into regulatory problems...it has to do with what percentage of the company they would.now control...this would require a special resolution by the board...an open vote by all the shareholders and scrutiny by the govt regulators. Could.really ...more  
Comment by M101 on Apr 16, 2021 1:45pm
Which is why the deal included the right participate in future financings on a prorated basis.  But it hardly matters as there are multiple corporate entities linked at arm's length.  And while the rationale is to prevent an unfriendly takeover it has also been highy advantageous to the existing incompetent management who, again with their focus- (and spend) on-everything statement ...more  
Comment by retiredcop on Apr 15, 2021 12:40pm
You may have overlooked something.. you mentioned that there were millions of shares bought... how about m illions of shares SOLD.... this is where the short term porfit traders come into play. A few weeks ago they spotted a stock that was climbing and tons of volume. they bought with aniticpation that the stock could be making a breakout ... the stock moved from the low teens to the low 20's. ...more  
Comment by M101 on Apr 15, 2021 12:13pm
Thanks for the memories, those were some tepid aspirational hopey changey feelings. That's the kind of garbage you only pretend to bank on when it comes from your spouse.  When I read this list I rate 50/50 the chance that Elliot gets a life-time paid director's seat about the same as ever completing phase 3, but 99.9% that total management compensation expands before either happens. ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities